In 2011, studies concluded that treatment with imatinib mesylate leads to substantial clinical responses in a subset of patients with advanced melanoma harboring KIT alterations and dacarbazine-based chemotherapy as first-line treatment in non-cutaneous metastatic melanoma: a multicenter, retrospective analysis in Asia [102]. Here, KIT is linked to melanoma.